265 related articles for article (PubMed ID: 16892245)
1. Purification of intravenous immunoglobulin G from human plasma--aspects of yield and virus safety.
Buchacher A; Iberer G
Biotechnol J; 2006 Feb; 1(2):148-63. PubMed ID: 16892245
[TBL] [Abstract][Full Text] [Related]
2. Preparation, purification and virus inactivation of intravenous immunoglobulin from human plasma.
Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Banazadeh S
Hum Antibodies; 2010; 19(1):1-6. PubMed ID: 20555125
[TBL] [Abstract][Full Text] [Related]
3. [Technology of immunoglobulin production. I. Technological aspects of purification].
Volkov GL
Ukr Biokhim Zh (1999); 2006; 78(3):88-98. PubMed ID: 17100315
[TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance.
Radosevich M; Burnouf T
Vox Sang; 2010 Jan; 98(1):12-28. PubMed ID: 19660029
[TBL] [Abstract][Full Text] [Related]
5. Investigations of prion and virus safety of a new liquid IVIG product.
Stucki M; Boschetti N; Schäfer W; Hostettler T; Käsermann F; Nowak T; Gröner A; Kempf C
Biologicals; 2008 Jul; 36(4):239-47. PubMed ID: 18337119
[TBL] [Abstract][Full Text] [Related]
6. Viral safety characteristics of Flebogamma DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin.
Caballero S; Nieto S; Gajardo R; Jorquera JI
Biologicals; 2010 Jul; 38(4):486-93. PubMed ID: 20350815
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization.
Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Sharifi Z
Hum Antibodies; 2008; 17(3-4):79-84. PubMed ID: 19029665
[TBL] [Abstract][Full Text] [Related]
8. Human intravenous immunoglobulin preparation and virus inactivation by pasteurization and solvent detergent treatment.
Chang CE; Eo HG; Lee YS; Chung SK; Shin JS; Lah YK; Park CW; Jung JT; Huh JW; Lee SM
Prep Biochem Biotechnol; 2000 Aug; 30(3):177-97. PubMed ID: 10919559
[TBL] [Abstract][Full Text] [Related]
9. Pathogen safety of human C1 esterase inhibitor concentrate.
Gröner A; Nowak T; Schäfer W
Transfusion; 2012 Oct; 52(10):2104-12. PubMed ID: 22413956
[TBL] [Abstract][Full Text] [Related]
10. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
11. Prion-removal capacity of chromatographic and ethanol precipitation steps used in the production of albumin and immunoglobulins.
Thyer J; Unal A; Thomas P; Eaton B; Bhashyam R; Ortenburg J; Uren E; Middleton D; Selleck P; Maher D
Vox Sang; 2006 Nov; 91(4):292-300. PubMed ID: 17105604
[TBL] [Abstract][Full Text] [Related]
12. Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview.
Soluk L; Price H; Sinclair C; Atalla-Mikhail D; Genereux M
Am J Ther; 2008; 15(5):435-43. PubMed ID: 18806519
[TBL] [Abstract][Full Text] [Related]
13. The autoreactivity of therapeutic intravenous immunoglobulin (IVIG) preparations depends on the fractionation methods used.
Djoumerska I; Tchorbanov A; Pashov A; Vassilev T
Scand J Immunol; 2005 Apr; 61(4):357-63. PubMed ID: 15853919
[TBL] [Abstract][Full Text] [Related]
14. Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid.
Radomski KU; Lattner G; Schmidt T; Römisch J
BioDrugs; 2017 Apr; 31(2):125-134. PubMed ID: 28236170
[TBL] [Abstract][Full Text] [Related]
15. High dose intravenous immunoglobulin treatment: mechanisms of action.
Boros P; Gondolesi G; Bromberg JS
Liver Transpl; 2005 Dec; 11(12):1469-80. PubMed ID: 16315304
[TBL] [Abstract][Full Text] [Related]
16. Identification of target antigens of self-reactive IgG in intravenous immunoglobulin preparations.
Bussone G; Dib H; Dimitrov JD; Camoin L; Broussard C; Tamas N; Guillevin L; Kaveri SV; Mouthon L
Proteomics; 2009 Apr; 9(8):2253-62. PubMed ID: 19296548
[TBL] [Abstract][Full Text] [Related]
17. A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state-of-the-art process.
Teschner W; Butterweck HA; Auer W; Muchitsch EM; Weber A; Liu SL; Wah PS; Schwarz HP
Vox Sang; 2007 Jan; 92(1):42-55. PubMed ID: 17181590
[TBL] [Abstract][Full Text] [Related]
18. Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation.
Roberts PL; Dunkerley C; Walker C
Biologicals; 2012 Sep; 40(5):345-52. PubMed ID: 22658506
[TBL] [Abstract][Full Text] [Related]
19. Gamma irradiation of intravenous immunoglobulin.
Drohan WN; Miekka SI; Griko YV; Forng RY; Stafford RE; Hill CR; Mann DM; Burgess WH
Dev Biol (Basel); 2004; 118():133-8. PubMed ID: 15645683
[TBL] [Abstract][Full Text] [Related]
20. New developments in plasma fractionation and virus inactivation.
Morgenthaler JJ
Vox Sang; 2000; 78 Suppl 2():217-21. PubMed ID: 10938956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
